Alendronate increases BMD and decreases fracture risk, but does treatment need to continue indefinitely? Results from RCT testing continuation of drug vs placebo in nearly 2000 women are equivocal.

Due to concern about a possible link between bisphosphonates and cardiac arrhythmias, an observational study looked at whether alendronate use is related to incident atrial fibrillation risk in women.